Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company listed on Euronext Growth (ALCLS) and Nasdaq (CLLS), held its shareholders' general meeting on June 28, 2024, in Paris. Approximately 40% of shares were exercised during the meeting, resulting in the adoption of resolutions 1 through 28 and the rejection of resolution 29, aligning with management's recommendations. Detailed voting results and resolutions are accessible on Cellectis' official website.

Positive

• Adoption of resolutions 1 through 28, reflecting strong shareholder alignment with management's recommendations.

Negative

• Only 40% of shares were exercised, indicating potentially low shareholder engagement.

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4^th floor, 75013 Paris, France.

At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent with the recommendations of the management.

The detailed results of the vote and the resolutions are available on Cellectis’ website: https://www.cellectis.com/en/investors/general-meetings/

About Cellectis  

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). 

For further information on Cellectis, please contact:  

Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com 
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment

• Cellectis GM June 28, 2024 - PR voting results

FAQ

What were the outcomes of Cellectis' shareholders' meeting held on June 28, 2024?

At Cellectis' shareholders' meeting on June 28, 2024, resolutions 1 through 28 were adopted, while resolution 29 was rejected.

How many shares were exercised at Cellectis' shareholders' meeting in 2024?

Approximately 40% of shares were exercised at the shareholders' meeting.

Where can I find the detailed voting results of Cellectis' 2024 shareholders' meeting?

The detailed voting results are available on Cellectis' official website at https://www.cellectis.com/en/investors/general-meetings/.

What is the stock symbol for Cellectis?

Cellectis is listed on Euronext Growth under the symbol ALCLS and on Nasdaq under the symbol CLLS.

Did the management's recommendations align with the voting outcomes at Cellectis' 2024 shareholders' meeting?

Yes, the voting outcomes aligned with management's recommendations, with resolutions 1 through 28 adopted and resolution 29 rejected.